Palisade Bio to Participate in the Virtual Investor Management and KOL Roundtable Event
April 29 2022 - 8:05AM
Palisade Bio (Nasdaq: PALI), a clinical stage
biopharmaceutical company advancing therapies for acute and chronic
gastrointestinal (GI) complications, today announced that members
of management will participate in the Virtual Investor Management
and KOL Roundtable Event on Tuesday, May 3, 2022 at 10:00 AM ET.
Participating from the Palisade Bio management
team will be Tom Hallam, Ph.D., Chief Executive Officer, Michael
Dawson, M.D., Chief Medical Officer and Robert McRae, Senior Vice
President, Operations and Strategic Development.
Joining Palisade Bio management will be Key
Opinion Leader, David B. Hoyt, MD, FACS, MAMSE. Dr. Hoyt is the
Executive Director of the American College of Surgeons (ACS),
Founding Member of the ACS Academy of Master Surgeon Educators™,
Member of the ACS Steering Committee for the Academy, and Emeritus
Professor of Surgery at the University of California, Irvine.
As part of the virtual event, Palisade Bio will
discuss the importance of intestinal barrier health and how it is
developing targeted therapeutics to protect and repair the
integrity of the gastrointestinal tract. In addition to the
moderated portion of the event, investors and interested parties
will have the opportunity to submit questions. The Company will
answer as many questions as possible during the event.
A live video webcast of the Virtual Investor
Roundtable Event will be available in the Latest Events and
Presentations section of the Investor page of Palisade Bio website
(palisadebio.com). A webcast replay will be available two hours
following the live presentation and will be accessible for 90
days.
About LB1148 LB1148 is a
novel oral liquid formulation of the well-characterized digestive
enzyme inhibitor, tranexamic acid (“TXA”), with potential to both
reduce abdominal adhesions and help restore bowel function
following surgery. The therapy is being developed for
administration prior to major surgeries that are at risk of
disrupting the intestinal epithelial barrier. Evidence suggests
that the release of digestive proteases contributes to the
temporary loss of normal gastrointestinal function and the
formation of postoperative adhesions. By inhibiting the activity of
these digestive proteases, LB1148 has the potential to prevent
damage to GI tissues, accelerate the time to the return of normal
GI function, and shorten the duration of costly post-surgery
hospital stays.
The U.S. FDA has granted Fast Track designation
to LB1148 for two clinical indications: reduction of adhesions
following abdominal or pelvic surgery and treatment of
postoperative GI dysfunction in pediatric patients undergoing
cardiac surgery.
About Palisade
Bio Palisade Bio is a clinical stage
biopharmaceutical company advancing therapies that aid patients
suffering with acute and chronic gastrointestinal complications
stemming from post-operative digestive enzyme damage. Palisade
Bio’s innovative lead asset LB1148, advancing toward Phase 3, is a
protease inhibitor with the potential to both reduce abdominal
adhesions and help restore bowel function following surgery.
Positive data from Phase 2 trials of LB1148 demonstrated safety and
tolerability as well as a statistically significant improvement in
the return of bowel function and a decrease in the length of stay
in ICU and hospital compared to placebo. Palisade Bio believes that
its investigational therapies have the potential to address the
myriad health conditions and complications associated with the
chronic disruption to the gastrointestinal epithelial barrier. For
more information, please go to www.palisadebio.com.
Forward Looking StatementsThis
communication contains “forward-looking” statements, including,
without limitation, statements related to expectations regarding
Palisade’s plans for future presentations at investor conferences.
Any statements contained in this communication that are not
statements of historical fact may be deemed to be forward-looking
statements. These forward-looking statements are based upon
Palisade’s current expectations. Forward-looking statements involve
risks and uncertainties. Palisade’s actual results and the timing
of events could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, the Company’s
ability to advance its clinical programs and the uncertain and
time-consuming regulatory approval process. Additional risks and
uncertainties can be found in Palisade Bio’s Yearly Report on Form
10-K for the year ended December 31, 2021. Palisade
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in Palisade’s expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statements are based.
Palisade Bio ContactDawn
Hofmeisterir@palisadebio.com
Investor Relations ContactJTC
Team, LLCJenene Thomas 833-475-8247PALI@jtcir.com
Palisade Bio (NASDAQ:PALI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Palisade Bio (NASDAQ:PALI)
Historical Stock Chart
From Jul 2023 to Jul 2024